Abalos
Key Facts
| Invested since | 2019 |
| Based in | North Rhine-Westphalia |
About the company
Abalos Therapeutics has harnessed the unique immune stimulation of the arenavirus to develop a novel anti-cancer approach that provides the full breadth of the immune system’s power specifically against cancer cells. Through viral replication within cancer cells, Abalos’ arenavirus-based drug candidates are designed to awake precise innate and adaptive immune responses and activate all relevant immune cell types against primary tumors and metastases. Led by experienced biotech entrepreneurs and immunology pioneers, Abalos’ goal is to achieve a quantum leap in immuno-oncology.
Do you want to
know more about this company?
Abalos in the news
Zum Artikel
Abalos Therapeutics Launches with €12M Series A Round to Develop Novel Immuno-Virotherapies Against Cancer
More startups from Life Sciences
Refined Laser Systems GmbH, based in Münster, Germany, was founded in 2019 as a spin-off from University of Münster by Max Brinkmann, Tim Hellwig and Christoph Seidenstücker. The company’s core …
To the complete profileof Refined Laser Systems
Ebenbuild is a health tech pioneer that creates personalized treatment recommendations for mechanical ventilation and ICU patient care for clinical users. Founded in Munich in 2019, the company develops software …
To the complete profileof Ebenbuild
Draupnir Bio is a spin out company, from Aarhus University and the Max-Planck Society and establishing itself at the forefront of protein degradation. Draupnir’s novel and proprietary platform technology is …
To the complete profileof Draupnir Bio
Symphera is a Munich-based startup that is revolutionizing laparoscopic surgery with an innovative system designed to eliminate the need for manual instrument changes. Founded in 2023, Symphera was incubated at …
To the complete profileof Symphera
Exit
Development of antibody conjugate-based cancer therapeutics for solid tumors with high unmet needs that are otherwise difficult to treat Problem: Solid cancers are still very difficult to treat. Most treatments …
To the complete profileof Emergence Therapeutics
FundaMental Pharma GmbH (FMP) is developing new types of drugs that act as ‘molecular spacers’ and disrupt a death signaling complex in the brain. Using this pharmacological strategy, FMP scientists …
To the complete profileof FundaMental Pharma
Hamburg-based COLIPI is developing an industrial biotechnological process that transforms climate-damaging CO2 and carbon-containing industrial waste into Climate Oil. This product serves as a sustainable and climate-neutral alternative to palm …
To the complete profileof COLIPI
Exit
Fiagon develops a new medical navigation system for intraoperative process control and positioning of instruments for ENT, head-/ neck- and neurosurgery.
To the complete profileof Fiagon
Preventicus GmbH is developing smartphone-driven solutions to capture and analyze patients’ vital parameters for early preclinical risk screening of lifestyle-related illnesses. Seed funding for the Jena-based company is managed by …
To the complete profileof Preventicus
DyNAbind is offering innovative drug discovery products and services based on its proprietary Dynamic DNA-Encoded Library (D-DEL) technology platform. With D-DEL, DyNAbind can simultaneously screen hundreds of millions of compounds …
To the complete profileof DyNAbind
VACIS is the leading tissue engineering company for body-own blood vessels. The VACIS technology uses a synthetic rod which induces the formation of a new fully functional blood vessel providing …
To the complete profileof Vacis
Exit
The founders of Kumovis GmbH have set themselves the goal of enabling the additive production of plastic implants and are developing innovative 3D printers specifically for medical products. Kumovis focuses …
To the complete profileof Kumovis